AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

First-in-Human Expanded Cohort Study of Intrapleural Administration of TolueneSulfonamide in Patients With Malignant Pleural Effusion

RecruitingPhase 1, Phase 2Ages 18 Years - 75 YearsAllGang Hou
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This study aims to evaluate the safety of intrapleural injection of TolueneSulfonamide in patients with malignant pleural effusion and to explore its potential effectiveness.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Age between 18 and 75 years (inclusive) at the time of signing the informed consent form. 2. Histologically or cytologically confirmed malignant pleural effusion, with the primary tumor diagnosed as non-small cell lung cancer (NSCLC). 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, with an expected survival of at least 3 months. 4. Presence of dyspnea symptoms. 5. No prior local thoracic treatment within 1 month before enrollment, including intrapleural drug administration or thoracic radiotherapy (diagnostic thoracentesis is permitted). 6. Except for the subject's current stable systemic anti-tumor therapy, any other ongoing tumor-related treatments must be suspended or discontinued after evaluation by the investigator to ensure they do not interfere with the assessment of PTS treatment. 7. Fully understands the study objectives and procedures, agrees to participate in the study, and provides written informed consent. Exclusion Criteria: 1. History of allergy or hypersensitivity to PTS or any of its excipients. 2. Presence of uncontrolled intrapleural infection or severe loculated pleural effusion that is difficult to manage. 3. Participation in another interventional clinical study within 3 months prior to enrollment (diagnostic studies are excluded). 4. Severe organ dysfunction, including but not limited to coagulation disorders, congestive heart failure, malignant arrhythmias, coronary artery disease requiring long-term medication, valvular heart disease, myocardial infarction, or refractory hypertension; severe cardiac, hepatic, or renal insufficiency, or active bleeding or thrombotic risk. 5. Presence of uncontrolled infectious wounds. 6. Pregnant or breastfeeding women. 7. Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation in this study. 8. Criteria for withdrawal from the study.
๐Ÿ’Š

What it tests

  • Intrapleural administration of TolueneSulfonamide
  • Intrapleural administration of normal saline injection
๐Ÿ“

Where

1 site
China-Japan Friendship Hospital
Beijing, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy